Skip to main content
. Author manuscript; available in PMC: 2013 Nov 4.
Published in final edited form as: Am J Transplant. 2011 Aug 10;11(11):10.1111/j.1600-6143.2011.03683.x. doi: 10.1111/j.1600-6143.2011.03683.x

Figure 3. Development of minimal costimulatory regimen.

Figure 3

Mean percent repopulation of donor cells in each WBC lineage in presensitized μMT B6 mice over time as measured by flow cytometry. μMT B6 mice presensitized with B10.A skin received the following conditioning regimens along with 3 Gy TBI and 80 × 106 B10.A BMCs. (A) Group A: anti-CD8 and anti-CD40L; Group B: anti-CD8, anti-CD4 and anti-CD40L; Group C: anti-CD8, anti-CD4, anti-CD40L and anti-OX40L. The incidence of chimerism was 100% in all groups. The right-hand panel demonstrates donor and third-party skin graft (SG) survival in B10.A→μMT B6 chimeras. Skin was grafted 8 weeks after allogeneic BMT. (B) Group A: anti-CD4 (1.76 mg), anti-CD8 (1.44 mg) and anti-CD40L (2.0 mg); Group B: anti-CD4, anti-CD8 and 0.5 mg of anti-CD40L; Group C: Two doses of anti-CD4 (1.76 mg each) and anti-CD8 (1.44 mg each) without anti-CD40L. All mice in Groups A and B and 14 of 15 mice in Group C achieved chimerism. The right-hand panel demonstrates donor and third-party SG survival in B10.A→μMT B6 chimeras. All grafted chimeric mice accepted donor-type SGs long term. Skin was grafted at least 9 weeks after allogeneic BMT.